Troplasminogen alfa

Drug Profile

Troplasminogen alfa

Alternative Names: BB-10153; Tapgen; V-10153

Latest Information Update: 17 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Vernalis
  • Class Anti-ischaemics; Antiarrhythmics; Plasminogen activator enzymes; Thrombolytics
  • Mechanism of Action Fibrinolytic agents; Plasmin stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Myocardial infarction; Stroke

Most Recent Events

  • 10 Oct 2018 Vernalis has been acquired by Ligand Pharmaceuticals
  • 25 Aug 2015 Discontinued - Phase-II for Stroke in USA, Canada, Czech Republic, Denmark and Hungary (IV)
  • 12 Nov 2010 V 10153 is available for licensing in World as of 28 Feb 2000. http://www.vernalis.com/
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top